Ropinirole
From Wikipedia, the free encyclopedia
 |
|
 |
|
|
Ropinirole
|
|
| Systematic (IUPAC) name | |
| 4-(2-dipropylaminoethyl)-1,3-dihydroindol-2-one | |
| Identifiers | |
| CAS number | |
| ATC code | N04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C16H24N2O |
| Mol. mass | 260.375 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 50% [1] |
| Metabolism | hepatic (CYP1A2) [1] |
| Half life | 5-6 hours[1] |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C |
| Legal status |
℞ Prescription only |
| Routes | Oral |
Ropinirole (marketed under the brand names Requip and Ropark) is a non-ergoline dopamine agonist. It is manufactured by GlaxoSmithKline and Sun Pharmaceuticals. It is used in the treatment of Parkinson's disease, and is also one of two medications in the United States with an FDA-approved indication for the treatment of restless legs syndrome (the other being pramipexole).
Ropinirole's patent expired on May 2008, and is now available in generic form. [2]
Contents |
[edit] Dosing
Requip (it is marketed as Adartrel in Europe for the restless legs syndrome indication and as Requip for the anti-Parkinson indication) is available in various preparations, ranging from the .25 mg tablet to the 5 mg tablet. The primary reason for such is dose titration. This implies that the person taking Requip has to closely interact and communicate with the primary care physician with regard to how much should actually be taken by the patient.
For restless legs Syndrome (RLS), the maximum recommended dose is 4 mg per day, taken 1 to 3 hours before bedtime. A 52-week open label study had a mean dosage of 1.90mg, once daily 1-3 hours before bedtime.[3]
For Parkinson's disease (PD), the maximum recommended dose is 24 mg per day, taken in three separate doses spread throughout the day.
[edit] Mechanism
Ropinirole acts as an agonist at the D2 and D3 dopamine receptor subtypes, binding with higher affinity to D3 than to D2 or D4 and It has no affinity for D1 receptors. It has medium in vitro affinity to opioid receptors. Ropinirole is weakly active at the 5-HT2, and α2 receptors and is said to have virtually no affinity to 5-HT1, benzodiazepine, GABA, muscarinic, α1, and β-adrenoreceptors.[4]
Ropinirole is metabolized primarily by cytochrome P450 CYP1A2, and at doses higher than clinical, is also metabolized by CYP3A4. At doses greater than 24mg, CYP2D6 may be inhibited, although this has only been tested in vitro.[1]
[edit] References
- ^ a b c d Tompson, Debra J. et al. (2007). "Steady-State Pharmacokinetic Properties of a 24-Hour Prolonged-Release Formulation of Ropinirole: Results of Two Randomized Studies in Patients with Parkinson’s Disease". Clinical Pharmacokinetics 29. doi:.
- ^ New pharmaceutical products: Ceftriaxon-Rocephin, Granisetron-Kytril, Ipratropium-Albuterol
- ^ Garcia-Borreguero, Diego et al. (2007). "A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome". Sleep Medicine 8: 742–752. doi:.
- ^ Eden, R. J. et al. (1991). "Preclinical Pharmacology of Ropinirole (SK&F 101468-A) a Novel Dopamine D 2 Agonist". Pharmacology Biochemistry & Behavior 38: 147–154.
[edit] External links
|
||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
